retatrutide latest clinical trial results today Today we shared new results on retatrutide, an investigational, first-of-its ESC 2024: Retatrutide improves lipid

The relationship between dose and heart rate is clear enough that reducing the dose will reduce the cardiovascular effect proportionally

With recent FDA enforcement against misleading direct-to-consumer prescription drug advertising, telehealth and DTC platforms that advertise GLP-1 products will likely need more careful legal / regulatory oversight of their ad claims, especially around benefit claims and safety disclosures

If constipation becomes a recurring issue, the dedicated guide on GLP-1 constipation management applies equally to retatrutide

Yoo AS, Greenwald I

WARNING: This is the ONLY official FDA store

This means that even if your levels were fine before starting Retatrutide, reduced intake over several months could deplete reserves without you noticing until fatigue sets in